Ending coverage does not merely stop progress. It reverses it—and costs may return as diabetes, CPAP equipment, additional medications, disability, and hospital care.
GLP-1 drugs
Posted inOpinion
‘The Pitt’ showed us the stigma patients with obesity face. Massachusetts policies cutting GLP-1 drug coverage reflect the same biases.
Policymakers must work with insurers and GLP-1 manufacturers to make sure these life-changing therapies remain accessible. Blanket denials of coverage will harm patients, invite long-term costs, and worsen the stigma we should be fighting against.
Posted inOpinion
Healey’s veto of funding for GLP-1 drugs harms public employees and the economy
Shouldn’t Massachusetts lead the way, rather than leave its citizens behind on this critical issue?
